SUMMARY

SUBJECTS AND METHODS
Patients:
The study population comprised 147 patients (118 men and 29 women with a mean age of 53 years) with DCM who were admitted to our hospital between August 1981 and June 1991. DCM was identified as a heart muscle disease of unknown cause characterized by left ventricular (LV) dilatation and systolic dysfunction, as shown by a LV end-diastolic dimension >55mm and fractional shortening <25%. Coronary artery disease was excluded by the absence of angina and myocardial infarction in a patients history and coronary angiography. Patients with hypertension (higher than 165/95mmHg), viral myocarditis in previous months (infectious history, positive serology, and myocardial biopsy findings), cor pulmonale, organic valve disease, congenital heart disease or specific heart muscle disease were excluded.
For our study, a patient was categorized as a "transient AF" patient when he or she was experiencing AF upon hospital admission but was restored to sinus rhythm (SR) upon discharge. Patients with persistent AF were divided into two groups according to the mean heart rate on standard 12-lead electrocardiograms at discharge: "rate-controlled" AF represented a heart rate of less than 90 beats/ min and "rate-uncontrolled" AF patients had a heart rate of 90beats/min or more. Echocardiographic studies and measurements: M-mode and two-dimensional echocardiographic images were obtained using either a Toshiba SSH 65A or 160A ultrasound imager. Standard two-dimensional echocardiographic images were obtained in the parasternal long-axis and short-axis, as well as in apical two-chamber and four-chamber views. The end-diastolic and end-systolic dimensions of the left ventricle, percent fractional shortening, and the left atrial dimension were obtained by M-mode echocardiogram. Cardiac catheterization:
Left-and right-sided heart catheterization, left and right ventricular angiography, and selective coronary angiography were performed in 116 patients after in-hospital optimization of medical therapy. An endomyocardial biopsy was obtained transvenously from the right ventricle in 83 patients, and three to five biopsy specimens were obtained from each patient. Cell diameter was measured in 50 cells from each biopsy, and percent myocardial fibrosis was determined in azan-stained preparations by a point counting method. Thallium 201 scintigraphy:
Thallium 201 scintigraphy was performed in 127 patients who were at rest. For semi-quantitative analysis, the severity of the were still alive, 24 patients (16%) had died of progressive heart failure, 9 patients (6%) had died suddenly, and 1 patient had died of non-cardiac causes. The fiveyear actuarial survival of AF patients compared with that of SR patients is shown in Figure 1 . At 5 years, the survival rate of patients with AF was significantly better than for those with SR (93% versus 68%, p<0.05). The NYHA functional classifications of AF patients improved in 20 out of 36 (56%) and deteriorated in 3 (8%), but those of the SR patients improved in only 30 (27%) and deteriorated in 10 (9%) (p<0.01) (Fig.2) . CTR, LV dimension and percent fractional shortening remained unchanged and the left atrial dimension was enlarged in SR patients, whereas CTR, LV end-systolic dimensions and fractional shortening improved significantly in AF patients (Fig.3) . For the purpose of excluding any effect of beta-blockade, which was used Jpn. Heart J. November, 1993 Fig.3 . Changes in heart rate, cardiothoracic ratio (CTR), and echocardiographic parameters between initial (solid bar) and follow-up study (hatched bar) in patients with atrial fibrillation (AF, n=36) versus with sinus rhythm (SR, n=111). Abbreviations as in Table I . more frequently in AF patients, the follow-up data of AF and SR patients with and without beta-blocker administration were compared. In patients treated with beta-blockers, the presence of AF did not confer a decreased risk (5-year survival of 100% versus 80%, P=NS), also LV fractional shortening improved significantly in AF patients and tended to improve in SR patients according to the follow-up Fig.4 . Changes in heart rate (HR), cardiothoracic ratio (CTR), and echocardiographic parameters between initial and follow-up. Abbreviations as in Table I. study.
In (Fig.4) .
DISCUSSION
In this study, the incidence of atrial fibrillation (AF) was 24% in 147
Jpn. Heart J. November, 1993 patients with DCM. Similar figures on the incidence of AF have been previously published.1)-4) Atrial arrhythmias in DCM are probably due to myocardial cellular abnormalities, as well as to chamber dilatation. The mechanism of their initiation remains uncertain. It has been unclear whether the tachyarrhythmia observed in DCM patients was the primary cause of the cardiomyopathy, or whether a secondary condition, resulting from mechanisms compensating for heart failure, was responsible.16) The effect of AF on survival is controversial. Our study demonstrated that DCM patients with AF had a significantly higher actuarial survival rate than patients with SR. Convert et al15) obtained similar information in a study of 132 patients with DCM, whereas other authors reported increased mortality among patients with AF.5)-7) These discrepancies might be explained by differences in basal cardiac conditions or treatment. In our study, the NYHA functional classification and echocardiographic parameters (LV dimension and fractional shortening) improved in AF patients, particularly in patients with "transient" and "rate -controlled"
AF . There were no differences in the clinical, echocardiographic, and hemodynamic parameters between AF and SR patients at the time of baseline evaluation. However, since electrocardiographic abnormalities (left bundle branch block and abnormal Q waves) were more frequent and the myocardial biopsy findings generally more severe in patients with SR than in those with AF, basal myocardial damage might be milder in AF patients than in SR patients despite their sharing clinical features and echocardiographic findings at the time of initial study. Thus, the improved symptoms and the increase in LV function were probably due to the removal of deteriorative factors (i.e., tachycardia and lack of active atrial systole17)). Chronic supraventricular tachycardia, such as atrial fibrillation, has been shown to produce dilated, congestive cardiomyopathy in humans and experimental animals.18)-24) Several recent clinical reports have documented an improvement in clinical symptoms, a decrease in LV volume and an increase in the systolic ejection fraction after the successful treatment of supraventricular tachycardia.19)-21),25),26) The underlying pathophysiologic link between chronic incessant tachycardia and ventricular dysfunction is unknown,16) but might be explained by ultrastructural and metabolic changes.22)
In regard to the treatment, we used warfarin more frequently in AF than in SR patients (89% vs 65%, p<0.01). Fuster et al9) argued that the presence of atrial fibrillation would lead to a higher risk of embolism as a cause of death. In the present study there was no fatal thromboembolic event, so warfarin can be used to prevent embolic events and to improve the survival rate of AF patients. A beta-blocker was used more frequently in AF patients than in SR patients (33% vs 11%, p<0.001), mainly for the purpose of slowing the heart rate. In patients without beta-blacker administration, AF patients had a significantly better 5-year survival rate than SR patients, and the LV end-systolic dimension and fractional shortening improved in AF patients but not in SR patients. However, in patients treated with a beta-blocker, the presence of AF did not confer a decreased risk, and while LV fractional shortening improved significantly in AF patients, it also tended to improve in SR patients. Recently, beta-blockers have been suggested as a means of improving the survival rate of patients with DCM. The mechanism of this beneficial action of beta-blockade may be related, in addition to its negative chronotropic effect with reduced myocardial oxygen demand, to 1) an increase in myocardial energy available for synthetic and reparative processes, 2) improvement in diastolic relaxation, filling, and compliance, 3) inhibition of sympathetically mediated vasoconstriction via prostaglandins and renin release, 4) protection against catecholamine-induced myocardial damage and necrosis, and 5) upregulation of beta-adrenergic receptors, allowing the restoration of catecholamine responsiveness.27) These beneficial effects might also relate to the good prognosis of AF patients.
This study suggested that atrial fibrillation could cause significant LV dysfunction in patients without underlying cardiomyopathy, or could exacerbate an underlying cardiomyopathic process. Therefore, aggressive antiarrhythmic therapy should be considered for patients initially diagnosed with dilated cardiomyopathy and atrial fibrillation.
